Genmab — Marts 2019
-
God morgen.
-
on split dosis administration (only front page) https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1576871?scroll=top&needAccess=true
-
MAIA under the microscope — bringing trial design into focus - by our big friend Vincent Rajkumar https://www.nature.com/articles/s41571-019-0198-0?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+nrclinonc%2Frss%2Fcurrent+(Nature+Reviews+Clinical+Oncology+-+Issue)
-
Tak E L.
-
Hvad er rajkumars anke?
-
Et gæt på 2019 salgstal som rammer minimum guidance: http://www.proinvestor.com/?p=debat_1&postid=76753&thread=50&start=
-
@solsen...men særdeles højt profileret inden for MM...https://www.mayo.edu/research/faculty/rajkumar-s-vincent-m-d/bio-00085953
-
Nogen der har adgang til artiklen?
-
Det Rajkumar mener, såvidt jeg har forstået, er at OS (overall survival) ikke forbedres med dara i first line, fordi patienterne vil få dara i second line, og derved få samme OS ? Problemet er vel at sygdommen kan forværres hvis de ikke får den bedste behandling. Underligt han ikke ønsker det bedste for dem...
-
Gary her har fx fået ødelagt sine nyrer af sygdommen, men er nu startet på dara (chemo) https://www.youtube.com/watch?v=o9eLPF8YgHk
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind